Biogen
BIIB · NASDAQ
Bulios Fair Price
$218.93
0.8% upside
Trenutna cena
$217.15
Po podatkih Bulios Fair Price se delnica BIIB trenutno trguje blizu svoje poštene vrednosti. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher A. Viehbacher
Employees
7,500
Headquarters
Cambridge
Prihajajoči dogodki
Earnings
Upcoming earnings report